OPTN

Upgrade to FINVIZ*Elite to get real-time quotes, intraday charts, and advanced charting tools.

Dollar change -0.03
Percentage change -0.33	%

Peers: BCRX ARQT KALA XNCR OCUL EYPT OVID ACHC LIN PETS

Index	-	P/E	-	EPS (ttm)	-2.93	Insider Own	21.93%	Shs Outstand	10.06M	Perf Week	-0.11%
Market Cap	92.54M	Forward P/E	-	EPS next Y	-1.18	Insider Trans	-0.81%	Shs Float	7.90M	Perf Month	61.77%
Income	-21.61M	PEG	-	EPS next Q	-0.74	Inst Own	58.37%	Short Float	3.44%	Perf Quarter	45.63%
Sales	78.22M	P/S	1.18	EPS this Y	-19.03%	Inst Trans	-9.39%	Short Ratio	3.37	Perf Half Y	-12.95%
Book/sh	-4.01	P/B	-	EPS next Y	53.43%	ROA	-18.28%	Short Interest	0.27M	Perf Year	-59.38%
Cash/sh	8.34	P/C	1.10	EPS next 5Y	-	ROE	-	52W Range	4.82 - 22.50	Perf YTD	36.83%
Dividend Est.	-	P/FCF	-	EPS past 5Y	44.26%	ROI	-	52W High	-59.38%	Beta	-0.82
Dividend TTM	-	Quick Ratio	0.70	Sales past 5Y	19.85%	Gross Margin	90.38%	52W Low	89.82%	ATR (14)	0.51
Dividend Ex-Date	-	Current Ratio	0.77	EPS Y/Y TTM	44.46%	Oper. Margin	-20.86%	RSI (14)	81.37	Volatility	1.29% 6.02%
Employees	128	Debt/Eq	-	Sales Y/Y TTM	10.19%	Profit Margin	-27.63%	Recom	3.00	Target Price	9.00
Option/Short	No / Yes	LT Debt/Eq	-	EPS Q/Q	97.68%	Payout	-	Rel Volume	1.50	Prev Close	9.17
Sales Surprise	7.61%	EPS Surprise	95.06%	Sales Q/Q	12.85%	Earnings	Mar 26 BMO	Avg Volume	80.62K	Price	9.14
SMA20	37.99%	SMA50	46.46%	SMA200	-12.60%	Trades		Volume	120,561	Change	-0.33%

Date	Action	Analyst	Rating Change	Price Target Change
Mar-20-25	Downgrade	Lake Street	Buy → Hold
Jan-03-25	Reiterated	H.C. Wainwright	Buy	$5 → $18
Mar-11-24	Initiated	H.C. Wainwright	Buy	$5
Aug-21-23	Initiated	Lake Street	Buy	$3
Oct-21-22	Resumed	Jefferies	Buy	$5
Apr-07-21	Resumed	RBC Capital Mkts	Outperform	$17
Dec-18-19	Initiated	Cowen	Outperform	$25
Aug-08-18	Initiated	Cantor Fitzgerald	Overweight

Mar-26-25 10:02AM	Biotech Stock Roundup: SAVA Dives on Setback, ALNY Up on Update & More (Zacks)
08:10AM	OptiNose (OPTN) Reports Q4 Loss, Tops Revenue Estimates (Zacks)
07:16AM	OptiNose: Q4 Earnings Snapshot (Associated Press Finance)
07:00AM	Optinose Reports Fourth Quarter and Full Year 2024 Financial Results and Recent Operational Highlights (GlobeNewswire)
Mar-24-25 09:55AM	Wall Street Analysts Believe OptiNose (OPTN) Could Rally 143.06%: Here's is How to Trade (Zacks)
12:44PM	Loading…
Mar-21-25 12:44PM	OPTN Stock Soars 53% on Inking $330M Deal to be Acquired by Paratek (Zacks)
12:06PM	Earnings To Watch: OptiNose Inc (OPTN) Reports Q4 2024 Result (GuruFocus.com)
06:35AM	Why OptiNose Inc. (OPTN) Surged On Thursday? (InsiderMonkey)
Mar-20-25 06:59AM	OptiNose climbs after take-private deal with Paratek Pharma (SeekingAlpha) +52.50%
Mar-19-25 09:45PM	Optinose Cancels Fourth Quarter and Full Year 2024 Earnings Call (GlobeNewswire)
09:25PM	Paratek Pharmaceuticals to Acquire Optinose, Creating Significant Commercial Expansion Opportunities for XHANCE in Chronic Rhinosinusitis (CRS) (GlobeNewswire)
Mar-11-25 04:15PM	Optinose Announces Reporting Date for Fourth Quarter and Full Year 2024 Financial Results (GlobeNewswire)
Jan-17-25 08:50AM	Optinose price target adjusted for stock split at Lake Street (TipRanks) +5.80%
Jan-15-25 07:00AM	Optinose Announces Preliminary Unaudited Fourth Quarter 2024 XHANCE Net Revenue of $22.4 Million (GlobeNewswire) +20.00%
Dec-26-24 07:00AM	Optinose Announces 1-for-15 Reverse Stock Split (GlobeNewswire) +9.72%
03:53PM	Loading…
Dec-02-24 03:53PM	Optinose to Present at the Piper Sandler 36th Annual Healthcare Conference (GlobeNewswire) +7.58%
Nov-13-24 02:06AM	OptiNose Inc (OPTN) Q3 2024 Earnings Call Highlights: Revenue Growth Amid Revised Guidance (GuruFocus.com) -15.47%
12:52AM	Q3 2024 OptiNose Inc Earnings Call (Thomson Reuters StreetEvents)
Nov-12-24 08:15AM	OptiNose (OPTN) Reports Break-Even Earnings for Q3 (Zacks) -21.90%
07:00AM	Optinose Reports Third Quarter 2024 Financial Results and Recent Operational Highlights (GlobeNewswire)
Nov-11-24 07:22AM	OptiNose Inc (OPTN) Q3 2024 Earnings Report Preview: What To Expect (GuruFocus.com)
Nov-05-24 04:30PM	Optinose Announces Reporting Date for Third Quarter 2024 Financial Results (GlobeNewswire) +5.95%
Oct-18-24 05:01PM	Rosalind Advisors, Inc. Expands Stake in OptiNose Inc (GuruFocus.com) +6.67%
Oct-16-24 04:05PM	Optinose Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire) +7.38%
Oct-09-24 05:30PM	OptiNose Inc (OPTN) Q2 2024 Earnings Call Highlights: Revenue Growth and Strategic Shifts Amid ... (GuruFocus.com)
Oct-07-24 04:59PM	Optinose Appoints Terry Kohler as Chief Financial Officer (GlobeNewswire)
Sep-05-24 09:00AM	New Peer-Reviewed Data Highlight the Benefits of XHANCE in Chronic Rhinosinusitis Patients with or without Prior Sinus Surgery (GlobeNewswire)
Aug-26-24 09:00AM	Optinose to Present at the H.C. Wainwright 26th Annual Global Investment Conference (GlobeNewswire)
Aug-08-24 08:25AM	OptiNose (OPTN) Reports Q2 Loss, Lags Revenue Estimates (Zacks) -9.52%
07:21AM	OptiNose: Q2 Earnings Snapshot (Associated Press Finance)
07:00AM	Loading…
07:00AM	Optinose Reports Second Quarter 2024 Financial Results and Recent Operational Highlights (GlobeNewswire)
Aug-02-24 08:30AM	Optinose Announces Reporting Date for Second Quarter 2024 Financial Results (GlobeNewswire)
Jul-02-24 04:27PM	7 Little-Known Penny Stocks That Can Turn $10K Into $1 Million (InvestorPlace)
Jun-27-24 07:00AM	Expanded Access to XHANCE with Addition to National Commercial Formularies (GlobeNewswire) +8.22%
May-17-24 12:00PM	Optinose to Present at the H.C. Wainwright 2nd Annual BioConnect Investor Conference at NASDAQ (GlobeNewswire)
May-15-24 05:15AM	Q1 2024 OptiNose Inc Earnings Call (Thomson Reuters StreetEvents)
03:07AM	OptiNose Inc (OPTN) Q1 2024 Earnings Call Transcript Highlights: Strategic Growth and Financial ... (GuruFocus.com)
May-14-24 11:53AM	OPTN Stock Earnings: OptiNose Misses EPS, Beats Revenue for Q1 2024 (InvestorPlace)
08:10AM	OptiNose (OPTN) Reports Q1 Loss, Tops Revenue Estimates (Zacks)
07:07AM	OptiNose: Q1 Earnings Snapshot (Associated Press Finance)
07:00AM	Optinose Reports First Quarter 2024 Financial Results and Recent Operational Highlights (GlobeNewswire)
May-10-24 03:51PM	OptiNose Inc (OPTN) Announces $55 Million Financing Round Amidst Revenue Projections (GuruFocus.com) +8.93%
02:56PM	Optinose Announces Reporting Date for First Quarter 2024 Financial Results (GlobeNewswire)
May-09-24 07:00AM	Optinose Announces $55 Million Registered Direct Offering (GlobeNewswire) +7.69%
May-02-24 10:01AM	Will OptiNose (OPTN) Report Negative Q1 Earnings? What You Should Know (Zacks)
Apr-25-24 10:51AM	Why Is OptiNose (OPTN) Stock Up 12% Today? (InvestorPlace)
07:00AM	Optinose Provides Corporate Update on XHANCE Launch and Outlook and Announces Preliminary First Quarter 2024 XHANCE Net Revenue of $14.9 million (GlobeNewswire)
Apr-04-24 04:01PM	Optinose to Present at the Needham Virtual Healthcare Conference (GlobeNewswire)
Mar-15-24 03:34PM	XHANCE Approved by FDA as First and Only Medication Indicated for Treatment of Adults with Chronic Rhinosinusitis without Nasal Polyps (GlobeNewswire)
Mar-08-24 09:50AM	OptiNose, Inc. (NASDAQ:OPTN) Q4 2023 Earnings Call Transcript (Insider Monkey)
Mar-07-24 09:41PM	Q4 2023 OptiNose Inc Earnings Call (Thomson Reuters StreetEvents)
01:54PM	OptiNose Inc (OPTN) Reports Decline in 2023 Revenue Amidst Preparations for Potential XHANCE ... (GuruFocus.com)
12:52PM	OPTN Stock Earnings: OptiNose Meets EPS, Beats Revenue for Q4 2023 (InvestorPlace)
08:15AM	OptiNose (OPTN) Reports Q4 Loss, Lags Revenue Estimates (Zacks)
07:33AM	OptiNose: Q4 Earnings Snapshot (Associated Press Finance)
07:00AM	Optinose Reports Fourth Quarter and Full Year 2023 Financial Results and Recent Operational Highlights (GlobeNewswire)
Feb-29-24 04:40PM	Optinose Announces Reporting Date for Fourth Quarter 2023 Financial Results (GlobeNewswire) +7.30%
Jan-18-24 12:00PM	Optinose Announces the Publication of ReOpen Phase 3 Clinical Trial Program Evaluating XHANCE in the Journal of Allergy and Clinical Immunology: In Practice (GlobeNewswire)
Dec-06-23 07:00AM	Optinose Announces 3-Month Extension of FDA Review Period for the Supplemental New Drug Application for XHANCE (GlobeNewswire) -16.33%
Nov-22-23 09:00AM	Optinose to Present at the 35th Annual Piper Sandler Healthcare Conference (GlobeNewswire)
Nov-11-23 11:37AM	OptiNose, Inc. (NASDAQ:OPTN) Q3 2023 Earnings Call Transcript (Insider Monkey)
Nov-09-23 08:05AM	OptiNose Inc (OPTN) Reports Q3 2023 Financial Results with Improved Operating Efficiency (GuruFocus.com)
07:25AM	OptiNose: Q3 Earnings Snapshot (Associated Press Finance)
07:00AM	Optinose Reports Third Quarter 2023 Financial Results and Operational Updates (GlobeNewswire)
Oct-27-23 08:00AM	Optinose Announces Reporting Date for Third Quarter 2023 Financial Results (GlobeNewswire)
Oct-24-23 12:00PM	OptiNose (OPTN) Upgraded to Buy: What Does It Mean for the Stock? (Zacks)
Sep-22-23 09:01AM	Optinose to Present at the 2023 Cantor Global Healthcare Conference (GlobeNewswire)
Aug-12-23 09:58AM	OptiNose, Inc. (NASDAQ:OPTN) Q2 2023 Earnings Call Transcript (Insider Monkey)
Aug-10-23 08:54PM	Q2 2023 OptiNose Inc Earnings Call (Thomson Reuters StreetEvents) +6.90%
08:25AM	OptiNose (OPTN) Q2 Earnings and Revenues Top Estimates (Zacks)
07:27AM	OptiNose: Q2 Earnings Snapshot (Associated Press Finance)
07:00AM	Optinose Reports Second Quarter 2023 Financial Results and Operational Updates (GlobeNewswire)
Aug-09-23 07:55PM	Profound Medical (PROF) Reports Q2 Loss, Misses Revenue Estimates (Zacks) -5.69%
Jul-27-23 07:00AM	Optinose Announces Preliminary Second Quarter 2023 XHANCE Net Revenue of $19.5 Million (GlobeNewswire)
Jul-07-23 08:28AM	When Will OptiNose, Inc. (NASDAQ:OPTN) Breakeven? (Simply Wall St.)
Jun-16-23 04:08PM	Optinose Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
Jun-10-23 08:16AM	OptiNose, Inc. (NASDAQ:OPTN) is definitely on the radar of institutional investors who own 39% of the company (Simply Wall St.)
Jun-02-23 01:00PM	Optinose to Present at the Jefferies Healthcare Conference (GlobeNewswire)
May-14-23 08:08AM	US$4.17: That's What Analysts Think OptiNose, Inc. (NASDAQ:OPTN) Is Worth After Its Latest Results (Simply Wall St.)
May-11-23 10:43PM	Q1 2023 OptiNose Inc Earnings Call (Thomson Reuters StreetEvents) +6.45%
08:55AM	OptiNose (OPTN) Reports Q1 Loss, Tops Revenue Estimates (Zacks)
07:54AM	OptiNose: Q1 Earnings Snapshot (AP Finance)
07:00AM	Optinose Reports First Quarter 2023 Financial Results and Operational Updates (GlobeNewswire)
May-04-23 07:00AM	Optinose Announces FDA Acceptance of Supplemental New Drug Application for XHANCE (GlobeNewswire) +11.43%
May-01-23 04:30PM	Optinose Announces Reporting Date for First Quarter 2023 Financial Results (GlobeNewswire)
Apr-18-23 12:43PM	OptiNose, Inc.'s (NASDAQ:OPTN) Business Is Trailing The Industry But Its Shares Aren't (Simply Wall St.)
08:00AM	Optinose Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
Apr-12-23 04:00PM	Optinose to Present at the Needham Virtual Healthcare Conference (GlobeNewswire)
Mar-11-23 07:29AM	OptiNose, Inc. (NASDAQ:OPTN) Q4 2022 Earnings Call Transcript (Insider Monkey)
Mar-09-23 06:24AM	We're Not Very Worried About OptiNose's (NASDAQ:OPTN) Cash Burn Rate (Simply Wall St.) -8.42%
Mar-07-23 11:22PM	Q4 2022 OptiNose Inc Earnings Call (Thomson Reuters StreetEvents)
08:35AM	OptiNose (OPTN) Reports Q4 Loss, Tops Revenue Estimates (Zacks)
07:00AM	Optinose Reports Fourth Quarter and Full Year 2022 Financial Results and Recent Operational Highlights (GlobeNewswire)
Mar-06-23 02:03AM	Silence Therapeutics PLC Sponsored ADR (SLN) Stock Jumps 9.3%: Will It Continue to Soar? (Zacks) +5.56%
Feb-28-23 04:30PM	Optinose Announces Reporting Date for Fourth Quarter 2022 Financial Results (GlobeNewswire)
Feb-21-23 02:29PM	Bucks County firm seeks to expand approval for flagship product (American City Business Journals)
07:00AM	Optinose Submits Supplemental New Drug Application for XHANCE Label Expansion (GlobeNewswire)
Jan-31-23 12:03PM	Optinose CEO Peter Miller resigns after 13 years; successor named (American City Business Journals)
07:00AM	Optinose Announces CEO Transition and Business Update (GlobeNewswire)
Dec-27-22 09:27AM	OptiNose, Inc.'s (NASDAQ:OPTN) top owners are private equity firms with 37% stake, while33% is held by institutions (Simply Wall St.)

OptiNose, Inc. operates as a pharmaceutical company. The firm engages in the development and commercialization of products for patients treated by ear, nose, throat, and allergy specialists. Its products include the XHANCE and ONZETRA Xsail. The company was founded by Per Gisle Djupesland and Helena Kyttari Djupesland in October 2000 and is headquartered in Yardley, PA.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
Marino Michael F III	Chief Legal Officer & Corp Sec	Mar 18 '25	Sale	5.61	246	1,380	55,038	Mar 19 02:48 PM
Mahmoud Ramy A	Chief Executive Officer	Mar 18 '25	Sale	5.61	368	2,064	126,563	Mar 19 02:46 PM
Michael F. Marino III	Officer	Mar 17 '25	Proposed Sale	5.37	242	1,300		Mar 14 06:41 PM
Ramy A Mahmoud	Officer	Mar 17 '25	Proposed Sale	5.37	363	1,949		Mar 14 06:37 PM
Spence Paul Jr.	Chief Commercial Officer	Mar 04 '25	Sale	5.29	1,223	6,470	32,647	Mar 04 05:32 PM
Marino Michael F III	Chief Legal Officer & Corp Sec	Mar 04 '25	Sale	5.29	2,145	11,347	55,284	Mar 04 05:31 PM
Mahmoud Ramy A	Chief Executive Officer	Mar 04 '25	Sale	5.29	6,376	33,729	126,931	Mar 04 05:29 PM
Michael F. Marino III	Officer	Mar 03 '25	Proposed Sale	5.81	2,100	12,201		Feb 28 09:08 PM
Paul Spence Jr.	Officer	Mar 03 '25	Proposed Sale	5.81	1,183	6,873		Feb 28 09:05 PM
Ramy A Mahmoud	Officer	Mar 03 '25	Proposed Sale	5.81	6,250	36,312		Feb 28 08:50 PM
Marino Michael F III	Chief Legal Officer & Corp Sec	Dec 17 '24	Sale	0.44	3,050	1,342	544,188	Dec 18 04:37 PM
Mahmoud Ramy A	Chief Executive Officer	Dec 17 '24	Sale	0.44	4,614	2,030	1,197,483	Dec 18 04:35 PM
Michael F. Marino III	Officer	Dec 17 '24	Proposed Sale	0.45	3,304	1,487		Dec 17 09:10 AM
Ramy A Mahmoud	Officer	Dec 17 '24	Proposed Sale	0.45	4,997	2,249		Dec 17 09:05 AM
Marino Michael F III	Chief Legal Officer & Corp Sec	Sep 17 '24	Sale	0.87	3,226	2,807	547,238	Sep 18 04:10 PM
Mahmoud Ramy A	Chief Executive Officer	Sep 17 '24	Sale	0.87	4,881	4,246	1,202,097	Sep 18 04:09 PM
Michael F Marino III	Officer	Sep 17 '24	Proposed Sale	0.89	3,226	2,871		Sep 16 08:37 PM
Ramy A Mahmoud	Director	Sep 17 '24	Proposed Sale	0.89	4,881	4,344		Sep 16 08:36 PM
Krick Anthony J	Chief Accounting Officer	Jul 17 '24	Sale	1.14	6,845	7,803	140,758	Jul 18 04:23 PM
Marino Michael F III	Chief Legal Officer & Corp Sec	Jul 17 '24	Sale	1.14	49,408	56,325	550,464	Jul 18 04:22 PM
Mahmoud Ramy A	Chief Executive Officer	Jul 17 '24	Sale	1.14	111,426	127,026	1,206,978	Jul 18 04:21 PM
Krick Anthony J	Chief Accounting Officer	Jun 18 '24	Sale	1.19	624	743	143,364	Jun 20 03:05 PM
Marino Michael F III	Chief Legal Officer & Corp Sec	Jun 18 '24	Sale	1.19	2,946	3,506	599,872	Jun 20 03:03 PM
Marino Michael F III	Chief Legal Officer & Corp Sec	Jun 18 '24	Sale	1.19	3,267	3,888	602,818	Jun 18 05:12 PM
Mahmoud Ramy A	Chief Executive Officer	Jun 18 '24	Sale	1.19	18,987	22,595	1,318,404	Jun 18 05:09 PM

open in yahoo | open in reuters | open in marketwatch | open in google | open in EDGAR

OptiNose Inc

Upgrade your FINVIZ experience